In agreement, antibodies against the most relevant cytokines have been developed, for instance, anti-IL-4/13 receptor (dupilumab), anti-IL-5 (mepolizumab, reslizumab) or anti-IL-5 receptor (benralizumab), and anti-IL-13 (lebrikizumab and tralokinumab) and anti-thymic stromal lymphopoietin (TSLP; tezepelumab), which have demonstrated efficacy in asthma patients who have been well stratified and whose endotypes have been correctly identified [77,78,79]. The gene discussed is TSLP; the disease is asthma.